Successful treatment of autoimmune hemolytic anemia with rituximab in a child with severe combined immunodeficiency following nonidentical T-cell-depleted bone marrow transplantation.
Bonduel
M
M
Zelazko
M
M
Figueroa
C
C
Magaldi
G
G
Rossi
J
J
del Pozo
A
A
D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D018572:Disease-Free Survival; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016130:Immunophenotyping; D007223:Infant; D007700:Kinetics; D008297:Male; D000069283:Rituximab; D016511:Severe Combined Immunodeficiency / Q000150:complications / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab